Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

First- and Second-Generation Antipsychotics for Children and Young Adults

Slide: 23 of 43

Efficacy of Second-Generation Antipsychotics: Placebo Comparisons, by Indication (3 of 3)

Second-generation antipsychotics (SGAs) have been compared to placebo to evaluate the clinical benefit achieved with their use.

For treatment of pervasive developmental disorder, a meta-analysis of Aberrant Behavior Checklist (ABC) scores from 3 studies of 202 participants showed that the score is 18.29 points lower with SGAs; the statistically valid range is from 9.51 to 27.08 points lower. A meta-analysis of CARS (Childhood Autism Rating Scale) scores from 2 studies of 62 participants showed that the score is 4.94 points lower with SGAs; the statistically valid range is from 1.36 to 8.52 points lower. A meta-analysis of Children’s Yale-Brown Obsessive Compulsive Scale (CYBOCS) scores from 3 studies of 325 participants showed that the score is 1.71 points lower with SGAs; the statistically valid range is from 0.25 to 3.17 points lower. The strength of evidence for these findings is low.

For treatment of attention deficit hyperactivity disorder/disruptive behavior disorders, a meta-analysis of ABC scores from 4 studies of 293 participants showed that the score is 20.97 points lower with risperidone. The statistically valid range is from 10.83 to 31.11 points lower.

A meta-analysis of Brief Pain Inventory (BPI) scores from 2 studies of 225 participants showed that the score is 3.77 points lower with risperidone; the statistically valid range is from 1.39 to 6.16 points lower. A meta-analysis of Clinical Global Impression-Improvement (CGI-I) scale scores from 3 studies of 380 participants showed that the score is 0.95 points lower with risperidone; the statistically valid range is from 0.25 to 1.66 points lower. A meta-analysis of Nisonger Child Behavior Rating Form (NCBRF) scores from 4 studies of 590 participants showed that the score is 6.93 points lower with risperidone; the statistically valid range is from 3.49 to 10.38 points lower. The strength of evidence for these findings is moderate.

Statistical Abbreviation: 95% CI = 95-percent confidence interval